Literature DB >> 9389927

Hodgkin's disease in patients older than 70 years of age: a registry-based analysis.

P D Forsyth1, E M Bessell, A J Moloney, I H Leach, J M Davies, J Fletcher.   

Abstract

Between 1973 and 1993, 529 patients aged 15 years and over with Hodgkin's disease (HD) were entered into a lymphoma registry. Twenty-eight cases (1 only diagnosed at autopsy) of histologically proven HD in patients aged 70 years or older were identified. The distribution of sex, 'B' symptoms, histology and stage was not significantly different from that of younger patients, except for the fact that there were no patients aged 70 years or older with lymphocyte predominant HD. Nineteen patients were treated radically, 5 patients palliatively and 4 patients received no radiotherapy or chemotherapy. Three of the 14 patients treated with chemotherapy achieved the planned dose intensity. The cause-specific 5-year survival was 75% for patients aged 15-69 years and 28% for patients aged 70 years and over (logrank chi(2) = 43.7, P < 0.00001). The younger and older groups treated with radical intent had complete response rates of 97% and 74%, respectively (logrank chi(2) = 17.91, P < 0.00001) and relapse rates at 5 years of 27% and 56%, respectively (logrank chi(2) = 4.86, P = 0.0275). The main reason for the poorer prognosis of patients aged 70 years and over was the increasing difficulty of chemotherapy delivery associated with advancing age.

Entities:  

Mesh:

Year:  1997        PMID: 9389927     DOI: 10.1016/s0959-8049(97)00119-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  2 in total

1.  ABVD as the treatment option in advanced Hodgkin's lymphoma patients older than 45 years.

Authors:  Bosko M Andjelic; Biljana S Mihaljevic; Ljubomir R Jakovic
Journal:  Pathol Oncol Res       Date:  2012-01-11       Impact factor: 3.201

2.  Long-term survival after treatment for Hodgkin's disease (1973-2002): improved survival with successive 10-year cohorts.

Authors:  E M Bessell; G Bouliotis; S Armstrong; J Baddeley; A P Haynes; S O'Connor; H Nicholls-Elliott; M Bradley
Journal:  Br J Cancer       Date:  2012-06-19       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.